Literature DB >> 7692919

Expression of CD59, a complement regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium.

K Koretz1, S Brüderlein, C Henne, P Möller.   

Abstract

CD59 (protectin) and CD46 (membrane cofactor protein, MCP) are membrane-bound complement regulator proteins which inhibit complement-mediated cytolysis of autologous cells. CD59, a phosphatidyl-inositol-anchored glycoprotein, inhibits the formation of the terminal membrane attack complex (MAC) of complement and was found to be a second ligand for CD2 contributing to T-cell activation. In 20 colorectal normal mucosa samples, in ten adenomas, 71 carcinomas and in ten liver metastases derived thereof, CD59 was inconsistently expressed in the epithelial compartment. In carcinomas CD59 expression in the whole neoplastic compartment was more often found in well- and moderately differentiated tumours. By contrast, focal expression or even complete lack of CD59 was more often found in poorly differentiated tumours (P = 0.021). In addition, carcinomas without metastases at the time of operation (Dukes A/B) more often expressed CD59 in the entire neoplastic population compared to those carcinomas which had already metastasised (P = 0.018). There was no correlation between the mode of CD59 expression in colorectal carcinomas and the tumour type or location. CD46 has C3b/C4b binding and factor-I dependent cofactor activity and is broadly expressed in various cells and tissues. In the epithelial compartment of normal colorectal mucosa, of all adenomas, carcinomas and their liver metastases, CD46 was expressed throughout the epithelial compartment. Since CD46 was consistently expressed in colorectal carcinomas the low expression or even lack of CD59 in a subset of tumours might not lead to critical complement-mediated attack of CD59-negative tumour cells. Regarding CD59 as a natural T-cell ligand involved in cognate T-cell-target-cell interaction, however, loss of CD59 might well be a selection advantage, provided that tumour antigen-mediated T-cell toxicity in colorectal carcinoma exists.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7692919      PMCID: PMC1968719          DOI: 10.1038/bjc.1993.456

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  34 in total

1.  Overlapping but nonidentical binding sites on CD2 for CD58 and a second ligand CD59.

Authors:  W C Hahn; E Menu; A L Bothwell; P J Sims; B E Bierer
Journal:  Science       Date:  1992-06-26       Impact factor: 47.728

2.  CD59 expressed by human endothelial cells functions as a protective molecule against complement-mediated lysis.

Authors:  R A Brooimans; A A Van der Ark; M Tomita; L A Van Es; M R Daha
Journal:  Eur J Immunol       Date:  1992-03       Impact factor: 5.532

Review 3.  CD59: a molecule involved in antigen presentation as well as downregulation of membrane attack complex.

Authors:  G T Venneker; S S Asghar
Journal:  Exp Clin Immunogenet       Date:  1992

4.  Decay-accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells.

Authors:  R W Finberg; W White; A Nicholson-Weller
Journal:  J Immunol       Date:  1992-09-15       Impact factor: 5.422

5.  Membrane attack complex (MAC)-mediated damage to spermatozoa: protection of the cells by the presence on their membranes of MAC inhibitory proteins.

Authors:  I A Rooney; A Davies; B P Morgan
Journal:  Immunology       Date:  1992-03       Impact factor: 7.397

6.  Structural properties of the glycoplasmanylinositol anchor phospholipid of the complement membrane attack complex inhibitor CD59.

Authors:  W D Ratnoff; J J Knez; G M Prince; H Okada; P J Lachmann; M E Medof
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

Review 7.  The role of surface HLA-A,B,C molecules in tumour immunity.

Authors:  P Möller; G J Hämmerling
Journal:  Cancer Surv       Date:  1992

Review 8.  MHC antigens and cancer: implications for T-cell surveillance.

Authors:  M J Browning; W F Bodmer
Journal:  Curr Opin Immunol       Date:  1992-10       Impact factor: 7.486

9.  The spread of rectal cancer and its effect on prognosis.

Authors:  C E DUKES; H J BUSSEY
Journal:  Br J Cancer       Date:  1958-09       Impact factor: 7.640

10.  Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas.

Authors:  K Koretz; S Brüderlein; C Henne; P Möller
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

View more
  8 in total

1.  Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid.

Authors:  N Donin; K Jurianz; L Ziporen; S Schultz; M Kirschfink; Z Fishelson
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

Review 2.  Membrane proteins: the key players of a cancer cell.

Authors:  Kim R Kampen
Journal:  J Membr Biol       Date:  2011-07-06       Impact factor: 1.843

3.  Expression of complement regulating factors in gastric cancer cells.

Authors:  T Inoue; M Yamakawa; T Takahashi
Journal:  Mol Pathol       Date:  2002-06

4.  Effect of IL-4 on altered expression of complement activation regulators in rat pancreatic cells during severe acute pancreatitis.

Authors:  Cheng Zhang; Chun-Lin Ge; Ren-Xuan Guo; San-Guang He
Journal:  World J Gastroenterol       Date:  2005-11-21       Impact factor: 5.742

5.  Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection.

Authors:  Juan Carlos Varela; Carl Atkinson; Robert Woolson; Thomas E Keane; Stephen Tomlinson
Journal:  Int J Cancer       Date:  2008-09-15       Impact factor: 7.396

6.  Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas.

Authors:  A Mäenpää; S Junnikkala; J Hakulinen; T Timonen; S Meri
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

7.  Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines.

Authors:  N Prang; S Preithner; K Brischwein; P Göster; A Wöppel; J Müller; C Steiger; M Peters; P A Baeuerle; A J da Silva
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

Review 8.  Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer.

Authors:  Saskia Meyer; Jeanette H W Leusen; Peter Boross
Journal:  MAbs       Date:  2014-10-30       Impact factor: 5.857

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.